Therapeutic vaccines against HIV infection.

摘要: Resistance to medication, adverse effects in the medium-to-long-term and cost all place important limitations on lifelong adherence combined antiretroviral therapy (cART). In this context, new therapeutic alternatives 'cART for life' HIV-infected patients merit investigation. Some data suggest that strong T cell-mediated immunity HIV can indeed limit virus replication protect against CD4 depletion disease progression. The combination of cART with immune restore and/or boost immune-specific responses has been proposed, ultimate aim being achieve a 'functional cure'. scenario, new, induced, HIV-specific would be able control viral undetectable levels, mimicking situation minority who without treatment do not progress AIDS. Classical approaches such as whole inactivated or recombinant protein initially proved useful vaccines. Overall, however, ability these early vaccines increase was very limited study results were discouraging, no consistent immunogenicity demonstrated there clear impact load. Recent years have seen development based more innovative vectors DNA, dendritic cells. Most clinical trials their induce responses, although they show efficacy terms controlling replication. However, some preliminary cell-based are most promising candidates. To improve effectiveness vaccines, better understanding mechanisms protection, virological deterioration is required; knowledge, an efficacious vaccine will remain elusive.